Related Experiment Video

Updated: Jun 10, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

MicroRNA-21 as therapeutic target in cancer and cardiovascular disease

Désirée Bonci1

  • 1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, Rome, Italy. desiree.bonci@iss.it

Recent Patents on Cardiovascular Drug Discovery
|July 24, 2010
PubMed

Insights

MicroRNAs (miRNAs), specifically miR-21, are implicated in cancer and heart disease. Inhibiting miR-21 shows promise as a therapeutic strategy for both conditions.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.
  • Dysregulated miRNAs are linked to diseases like cancer and cardiac conditions.
  • miR-21 is consistently upregulated in both cancer and cardiovascular diseases, acting as an oncomir.

Purpose of the Study:

  • To review the patent landscape for therapeutic applications of miR-21 modulation.
  • To highlight miR-21's role as a potential therapeutic target in oncology and cardiology.

Main Methods:

  • Literature review of scientific publications and patent databases.
  • Analysis of studies investigating miR-21's function in cancer and cardiovascular systems.
  • Examination of therapeutic interventions targeting miR-21.

Main Results:

  • miR-21 promotes oncogenic activity and contributes to cardiac fibrosis and heart failure.
  • Inhibition of miR-21 reduced breast cancer growth in preclinical models.
  • Therapeutic antagonism of miR-21 improved cardiac function and ameliorated pressure-overload effects in mouse models.

Conclusions:

  • miR-21 is a validated therapeutic target for both cancer and cardiovascular diseases.
  • Modulation of miR-21, particularly inhibition, holds significant therapeutic potential.
  • The patent landscape reflects the growing interest in miR-21-based therapies.

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...